Federal Register #2026-16439

NCI Seeks Partners for QPID Autoradiography System, RO4 Antibody, and Humanized Thrombosis Antibodies

The National Cancer Institute (NCI), part of the National Institutes of Health, is seeking licensees and co-development partners for several innovative biomedical technologies: - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Technology Transfer Center - Key Technologies and OEMs: - QPID Digital Autoradiography System - Utilizes the Timepix3 detector (noted OEM: Advacam, Medipix Consortium) - Prototype device for quantitative particle identification in autoradiography - Differentiates between alpha, beta, and gamma particles - Improves radiotherapy dosing, guidance, and biopsy accuracy - RO4 Monoclonal Antibody - Novel antibody targeting the juxta-membrane region of mesothelin - Enables development of CAR T cells and bispecific antibodies for mesothelin-positive cancers (mesothelioma, ovarian, pancreatic) - Humanized Antibodies 58B3 and 56E5 - Selectively neutralize soluble tissue factor (sTF) - Prevent pathological thrombosis while preserving normal hemostasis - Applications in cancer, sepsis, autoimmune, infectious, and cardiovascular diseases - Products/Services Requested: - Licensing and/or co-development partnerships for the above technologies - No specific quantities; focus is on technology transfer and collaboration - Unique/Notable Requirements: - Technologies are at the prototype or pre-commercial stage - Emphasis on improving specificity, sensitivity, and therapeutic effectiveness in oncology, radiology, and thrombosis management - QPID system's unique ability to distinguish particle types for theranostic applications - RO4 antibody's enhanced binding and cytotoxicity for targeted cancer therapy - Humanized antibodies' selective action on soluble tissue factor for safer thrombosis treatment

Description

The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for a Quantitative Particle Identification (QPID) digital autoradiography system. This system measures energy deposition from charged particles for individual radioactive decays, improving autoradiographic imaging quality. It uses the Timepix3 detector to differentiate alpha, beta, and gamma particles, aiding in the development of new theranostic treatments. The technology is at the prototype development stage and aims to improve radiotherapy dosing, guidance, and biopsy accuracy.

View original listing